OrthoGrid Systems, Inc., a global medtech leader in alignment technology for orthopedic surgery, announces that its newest application, PhantomMSK Trauma, has received 510(K) clearance from the U.S. FDA.

OrthoGrid Systems’ PhantomMSK is a universal software platform that works with all manufacturer devices across multiple procedures to assist with implant, instrument and anatomic alignment that use fluoroscopic imaging. It is the only intraoperative alignment technology on the market to correct the phenomenon of image distortion in orthopedic surgery, attributed to external electromagnetic interference and the mapping of the planar image on a curved input phosphor, affecting image integrity and causing potential risks of malalignment.

The new Trauma application joins several others on the PhantomMSK platform, including the Hip and Hip Preservation applications, that contribute to improved surgical accuracy and efficiency, leading to better patient outcomes.

The PhantomMSK Trauma application uses software features in conjunction with proprietary algorithms to correct fluoroscopic image distortion. To operate PhantomMSK Trauma, a fluoroscopic image is acquired from a C-arm displayed outside the sterile field, where the image analysis tools can be used at the surgeon’s discretion. OrthoGrid’s intelligence-guided systems are designed to work within the surgical theater flow and interface with existing hospital equipment leading to greater precision and contributing to reduced hospital re-admissions.

“This milestone represents years of scientific research and data, product development and our commitment to empowering surgeons in the OR with advanced decision support tools,” said Edouard Saget, co-founder and CEO of OrthoGrid Systems.

“We will continue to innovate in the market by using emerging technologies in an effort to drive value-based care that benefits patients, hospitals, and surgeons,” added co-founder and CEO of OrthoGrid Systems, Richard Boddington. The PhantomMSK Trauma application will be available in Spring 2020.

About OrthoGrid Systems, Inc.

OrthoGrid Systems is a global medtech leader offering intraoperative alignment technologies that work across all orthopedic implants in the market. Its AI-enabled systems and digital surgical instruments work within the surgical theater and interface with existing hospital equipment to reveal fluoroscopic image distortion and provide greater accuracy to enhance surgical outcomes. OrthoGrid Systems was founded in 2012 and is based in Salt Lake City, Utah, with research facilities located in Strasbourg, France, a growing bio-cluster, and is distributed throughout North America, Asia, and Europe. For more information, visit www.orthogrid.com.

Royal Philips , a global leader in health technology, and Florida-based Health First announced the outcomes of their successful 15-year tele-critical partnership. Powered by Philips’ acute telehealth platform eCareManager, Health First’s VitalWatch eICU has demonstrated significant reductions in mortality and lengths of stay for the health system’s sickest patient population. Leveraging eCareManager to synthesize patient data for actionable insights to support proactive care, Health First has created a centralized hub for patient care across venues beyond the ICU.

Significant ICU improvement results

Health First became Florida’s first tele-ICU when the organization went live with VitalWatch in September 2004 and remains the only tele-ICU hub in Central Florida. VitalWatch allows Health First’s critical care physicians and nurses to monitor real-time vital signs, laboratory results, and patients’ complete electronic medical records from a central location across 102 ICU beds at the four Health First hospitals. The VitalWatch staff can also direct a patient’s care on the spot via live audio and video connections to the patient’s room if needed.

To date, the VitalWatch eICU program has resulted in:

• 23 percent reduction in overall mortality across the four hospitals as a whole;
• 49 percent reduction in ICU length of stay; and
• 35 percent reduction in lengths of stay throughout the four hospitals [1].

VitalWatch monitors more than 10,000 patients each year. Annually, this vigilance has resulted in 48,000 interventions by eICU intensivists and registered nurses. Additionally, these teams have conducted more than 370,000 telemedicine assessments and managed 62,000 calls from bedside teams seeking to collaborate on patient care.

“As patient needs in the ICU become more complex and the clinician shortage continues to affect this department, providing proactive care and spotting deterioration in these patients is becoming more challenging for caregivers – particularly since patient conditions can change so rapidly,” said Carla Kriwet, Chief Business Leader of Connected Care at Royal Philips. “Philips is committed to helping deliver meaningful outcomes for health systems and patients, and this long-term collaboration with Health First represents how partnering around innovation can drive the desired longitudinal results.”

“Health First is proud of the exceptional outcomes that have occurred between our clinicians and VitalWatch to improve care for our critical care patients,” said Jeffrey Stalnaker, MD, Senior Vice President, Chief Physician Executive, Health First. “This partnership has evolved how healthcare is delivered in our hospitals. Not only does this technology allow us to provide exceptional care, it gives added comfort to the families who know there is always a compassionate and dedicated healthcare professional continually watching over their loved ones.”

Centralizing care to improve outcomes

Health First initially implemented the eICU to address the growing shortage of intensivists and has since expanded the program to help drive care standardization and minimize unwarranted care variation across patients and hospitals. By leveraging the continuous advancements of Philips eCareManager – including platform infrastructure and clinical performance applications – the organization has also scaled services beyond the ICU through the introduction of a Clinical Operations Center. The Clinical Operations Center drives centralized care with real-time, actionable analytics and proactive recommendations to enable patient progression based on their clinical condition, and to help ensure that patients are transitioned to the most appropriate care setting.

Philips is the global leader in centralized tele-critical care. More than 20% of US adult ICU beds and 1 in 8 adult ICU patients are monitored by a 24/7 continuous demand model powered by the Philips eICU Program, which combines A/V technology, predictive analytics, data visualization and advanced reporting capabilities [2, 3]. The core of this program is Philips eCareManager software, which delivers need-to-know information to caregivers, empowering them to care for the patients in a more proactive manner.

As part of its commitment to continuously evolve to meet the needs of a changing healthcare marketplace, Philips recently announced an eCareManager platform extension with the launch of Sentry Score, a predictive algorithm for the adult intensive care unit (ICU) that shows a patient’s probability of receiving an intervention within 60 minutes [4]. Philips tele-critical care platforms are available around the globe with clinical informatics applications supporting bedside, unit and virtual delivery models.

[1] Data and outcomes per quarterly benchmarking reports provided through Philips eCareManager system

[2] Representative of the total Philips eICU licensed beds as a percentage coverage relative to total US adult ICU beds

[3] Derived from SCCM Adult ICU admission statistic and compared to eCareManager eRI annual monitored patients https://www.sccm.org/Communications/Critical-Care-Statistics

[4] Sentry Score Development and Validation Among Patients Under Intensive Care

The U.S. FDA has cleared the SOMATOM go.Sim and SOMATOM go.Open Pro – two computed tomography (CT) systems from Siemens Healthineers that are dedicated for radiation therapy (RT) planning.

The 64-slice SOMATOM go.Sim and 128-slice SOMATOM go.Open Pro are members of the SOMATOM go. platform, which was created to limit potential errors in radiation therapy planning and reduce time to treatment. The platform integrates hardware and software components such as patient marking lasers and automated quality assurance to simplify the treatment planning process, while the 85 cm bore accommodates positioning accessories and improves patient comfort. An innovative mobile workflow walks the radiation therapist through the setup process while the therapist remains with the patient to reduce anxiety.

Since 75 percent of respiratory patients breathe irregularly, motion artifacts often appear in 4D image sets. The Direct Intelligent 4D (Direct i4D) technology of the SOMATOM go.Open Pro adapts image acquisition to patient breathing in real time to reduce those artifacts. Reducing unwarranted variations in the images can potentially decrease target margins, thereby sparing healthy tissue.

“With the FDA clearance of the SOMATOM go.Sim and SOMATOM go.Open Pro, Siemens Healthineers offers our customers revolutionary technology for radiation therapy planning,” said Hanno Dotzel, Vice President of Surgery and Cancer Therapy in the Advanced Therapies business at Siemens Healthineers North America. “The new i4D technology can help our customers dramatically reduce image artifacts, enabling them to reach a new level of precision in radiation therapy treatment planning.”

Bender – a global pioneer of electrical safety technology – will be launching their new future-proof operating theatre control panel at Arab Health 2020.

Bender’s latest COMTRAXX® CP9 product creates a user-friendly bridge between theatre staff and installed technology, providing clinical teams with a simple and intuitive method of controlling the entire theatre environment at the touch of a fingertip – including lighting, temperature and humidity, ventilation and critical alarms.

Designed for use in hospital and sterile areas, the new CP9 range control panels provide a technological upgrade to the hygienic touchscreen theatre control panels originally pioneered by Bender Group over 20 years ago.

While incorporating the same functionality as existing theatre control panels, the pioneering glass touch CP9 system provides a more customisable, intuitive and user-friendly interface – a central point where medical staff can control theatre equipment functions and receive alerts within the operating, recovery or critical care area.

The pioneering system is carefully designed to deliver high resolution images and central touch control for all connected systems within the operating theatre.

It is easily adaptable –manufactured in-house in standard or exact customer specifications – and can be re-programmed to accommodate any future theatre equipment changes. The panel also enables easy integration of external subsections such as charging stations for operating theatre table remote controls and intercom systems and requires minimal service interventions.

Lisa Hudson, Marketing Manager at Bender UK, comments: “Our new glass touch control panels are easy to operate and provide simple integration of connected systems in a single interface panel that is also capable of connecting to the hospital’s wider network.

“Hospital teams are under intense pressures – operating in difficult environments against a background of shortages and budget cuts. It is vitally important that the technical systems they rely on are intuitive, reliable and simple to use. We look forward to demonstrating how our new generation of control panels can meet the tough demands of modern medical locations, at Arab Health 2020.”

Bender’s full turnkey surgical solutions will also be showcased on the Association of British HealthTech Industries (ABHI) simulated operating theatre – a centrepiece of the UK Pavilion – where visitors will be able to see the company’s ground-breaking new generation of control panels in action, and how their surgical solutions are designed to fit together.

Visit Bender Group at Arab Health (27 January 2020 – 30 January 2020) for a demonstration of their new technology – H2.F03

For more information visit https://www.bender-uk.com

About Bender Group

A market leader in turnkey operating theatre solutions, Bender has been providing technological solutions to key industries worldwide for over 65 years – from oil & gas to renewable energy, mechanical engineering, and healthcare. The company is represented in over 70 countries around the world

Bender Group is a chosen partner of NHS Trusts, private medical groups, design consultants and facilities management companies, delivering resilient turnkey solutions for critical care hospitals worldwide. In the UK and ROI, Bender UK is a reputable market leader in the provision of critical care power and surgical packages for group 2 medical locations.

CVS Health announced Transform Oncology Care™, anchored on a first-of-its-kind precision medicine strategy for payors. The program uses genomic testing results at the point-of-prescribing to help patients start on the best treatment, faster and in addition, matches eligible patients to clinical trials. Transform Oncology Care also uses the Company’s local footprint and unique assets to improve patient outcomes and lower overall costs at every point of the cancer care journey.

Timing in cancer care is everything and when a patient does not get started on the right treatment it can result in progression and higher costs,” said Alan Lotvin, M.D., Executive Vice President and Chief Transformation Officer, CVS Health. “We are the first company working to make the latest in precision medicine accessible to more patients and further empower informed treatment decision-making based on a patient’s genetic profile to give them the best chance for successful treatment and improved quality-of-life.”

Connecting Guidelines to Genetic Testing for the Best Treatment, Faster
The innovative precision medicine strategy, delivered in close coordination with oncologists, uses results of broad-panel gene sequencing tests and the latest National Comprehensive Cancer Network (NCCN) treatment and supportive care guidelines to help oncologists identify and start their patients on the most precise, appropriate treatment regimen based on their clinical and genetic profiles. Therapeutic regimens that align to NCCN guidelines, including those matched with the results of the broad-panel gene sequencing tests, will automatically receive prior authorization approval, speeding time to start of the therapy for patients. The strategy is enabled by an innovative collaboration with Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare.

“CVS Health is making great strides in advancing patient care, and we are thrilled to contribute the benefits of genomic testing to these efforts,” said Ryan Fukushima, Chief Operating Officer of Tempus. “We believe this collaboration has real potential to personalize treatment for patients while also reducing the total cost of care.”

The majority of cancers when diagnosed early can be effectively managed, treated or even cured1. For patients diagnosed with late-stage cancers, however, many can benefit from advanced genomic testing, yet very few eligible patients receive this type of testing. This can inhibit the start of the most appropriate treatment and result in cancer progression and higher costs. For these patients, a web-based provider portal, built into the e-prescribing workflow, informs oncologists of the availability of Tempus’ broad-panel gene sequencing tests at diagnosis, which are more comprehensive than the single-gene tests that are used today. The broad-panel tests identify a patient’s genomic variants and the therapeutic options specific to their molecular and clinical profile. The testing results also match and help support the rapid enrollment of eligible patients in local clinical trials through Tempus’ proprietary platform, facilitating broader access to experimental therapies. In addition, the portal provides oncologists real-time access to the latest NCCN guidelines at the point-of-prescribing.

The program includes CVS Health nurse-led care management, integrated with payor’s existing programs, to create a more personalized experience for patients and their caregivers and close existing gaps in care. In addition, payors can adopt value-based contracts that employ provider networks to drive high-quality care and lower costs. Transform Oncology Care also uses the CVS Health’s accessible, local footprint, connected data and integrated systems to help better identify and intervene with patients who could benefit from preventive or screening services.

Transform Oncology Care is available to other health plans. Aetna has adopted the program for fully insured commercial populations and is rolling it out with participating Aetna provider networks in 12 states.

About CVS Health
CVS Health is the nation’s premier health innovation company helping people on their path to better health. Whether in one of its pharmacies or through its health services and plans, CVS Health is pioneering a bold new approach to total health by making quality care more affordable, accessible, simple and seamless. CVS Health is community-based and locally focused, engaging consumers with the care they need when and where they need it. The Company has approximately 9,900 retail locations, approximately 1,100 walk-in medical clinics, a leading pharmacy benefits manager with approximately 102 million plan members, a dedicated senior pharmacy care business serving more than one million patients per year and expanding specialty pharmacy services. CVS Health also serves an estimated 38 million people through traditional, voluntary and consumer-directed health insurance products and related services, including rapidly expanding Medicare Advantage offerings and a leading standalone Medicare Part D prescription drug plan. The Company believes its innovative health care model increases access to quality care, delivers better health outcomes and lowers overall health care costs. Find more information about how CVS Health is shaping the future of health at https://www.cvshealth.com.

Asia’s largest exhibition and conference dedicated to the Medical Device Design and Manufacturing industry, “Medtec Japan 2020” will be held in Tokyo from 16th Mon – 18th Wed March 2020.

Over 530 exhibitors from some 24 countries around the world exhibited their latest technologies and services last year in Japan, the second largest medical device market in the world after the United States. With a rapidly aging population and rising demand for increasingly sophisticated treatments, the medical devices industry is one of the few sectors that have seen continuous and steady growth.

Over 25,000 visitors attended the previous event from nearly 51 countries, including the United States, Europe, ASEAN countries, China, Korea and many more. Medtec Japan is a highly targeted event, with over 60% of visitors coming from medical device manufacturers. Among them are buyers and R&D staff from companies such as Terumo Corporation, Olympus Corporation, Nihon Kohden Corporation, OMRON Corporation, PHC Co., Ltd., Kawasumi Laboratories Inc., Nipro Corporation, Fukuda Denshi Co., Ltd., JMS Co., Ltd., Create Medic Co., Ltd., HOYA Corporation, Konica Minolta, Inc., Canon Medical Systems Corporation, Sysmex Corporation, FujiFilm Corporation, Toray Medical Co., Ltd., GC Co., Ltd., J. Morita Mfg. Corp, Yoshida Seisakusho Co., Ltd., and Eisakusho Co., Ltd.

About Medtec Japan 2020
Medtec Japan is one of the ten highly-focused life science related exhibitions that will be held concurrently in Tokyo under an umbrella “Japan Life Science Week 2020”. Japan Life Science Week provides a unique platform for the creation of new business opportunities in the field of medical devices and pharmaceuticals, as well as focusing world attention on Japan’s cutting-edge medical technologies.Medtec Japan 2020 will be held in Tokyo from 16th Mon – 18th Wed March 2020. For more information, please visit www.medtecjapan.com